Intec Pharma — Technical Presentation (July 2019)
9 slides from Intec Pharma's technical presentation, Jul 22, 2019
Slide 1: Phase 3 ACCORDANCE Study Top-Line Results July 22, 2019
Phase 3 ACCORDANCE Study Top - Line Results July 22 , 2019
Slide 2: Forward-looking statements
This presentation by Intec Pharma Ltd. (referred to as “we” or “our”) may contain forward - looking statements about our expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operation s, strategies, plans and pr
Slide 3: Parkinson's Disease and Levodopa
• Parkinson ’ s disease (PD ) results from a continuing loss of dopamine - producing nerve cells. • Dopamine is required for normal functioning of the central nervous system. • Levodopa is generally considered to be the most effective and widely used treatment for Parkinson ’ s disease. • Up to 50 %
Slide 4: The Accordion Pill: A new platform for oral drug delivery
The Accordion Pill: A new platform for oral drug delivery AP capsule dissolves and outer layers facilitate unfolding mechanism of films Layers comprise an inner, controlled release drug - containing layer, and immediate release layer(s) for multiple drug release profiles and/or fixed - dose combinat
Slide 5: AP-CD/LD Phase III Trial Design
AP - CD/LD Phase III Trial Design ~ 9 0+ Clinical sites across 10 countries 6 Weeks 13 Weeks 2 Weeks 50 / 400 , 50 / 500 BID, TID Open label N= 462 Double Blind 12 Months 6 Weeks Optimization on Sinemet® AP - CD/LD Conversion Enrollment Committee Review Treatment Period Sinemet + AP - CD/LD dummy Tr
Slide 6: Primary Analysis - Average Hours of OFF Time Daily
Primary Analysis - Average Hours of “ OFF ” Time Daily
Slide 7: Preliminary Post Ad Hoc Analysis - Patients Not Requiring Maximal AP Dose
Preliminary Post Ad Hoc Analysis - All Patients NOT Requiring The Maximal AP Dose of 1500 mg LD
Slide 8: Preliminary Post Ad Hoc Analysis - Patients Who Received 1.6 to 2.0 Dose Ratio
Preliminary Post Ad Hoc Analysis - Patients Who Received 1.6 to 2.0 Dose Ratio of AP LD to IR LD
Slide 9: Thank you www.intecpharma.com
Thank you www.intecpharma.com